Zobrazeno 1 - 10
of 61
pro vyhledávání: '"Tzamakou, E."'
Autor:
Briasoulis, E. *, Pentheroudakis, G., Karavasilis, V., Tzamakou, E., Rammou, D., Pavlidis, N.
Publikováno v:
In Annals of Oncology October 2004 15(10):1566-1573
Autor:
Briasoulis, E. *, Karavasilis, V., Anastasopoulos, D., Tzamakou, E., Fountzilas, G., Rammou, D., Kostadima, V., Pavlidis, N.
Publikováno v:
In Annals of Oncology June 1999 10(6):701-706
Autor:
Briassoulis, E. Ch, Karavasilis, V., Tzamakou, E., Piperidou, C., Soulti, K., Pavlidis, Nicholas
Publikováno v:
Anti-Cancer Drugs
The aim of this study is to investigate the feasibility and determine the pharmacokinetics of low-dose paclitaxel in cancer patients with severe hepatic dysfunction. This was a prospective study. Patients with liver metastases who had either transami
Autor:
Pentheroudakis, George, Briassoulis, E. Ch, Karavasilis, V., Mauri, D., Tzamakou, E., Rammou, D., Pavlidis, Nicholas
Publikováno v:
Chemotherapy
Purpose: We performed a phase I study of two fixed dosing schemes of cisplatin, a DNA cross-linker, with intravenous escalating topotecan, a DNA-topoisomerase I inhibitor. Experimental Design: 40 patients with advanced solid tumors received intraveno
Autor:
Briassoulis, E. Ch, Karavasilis, V., Tzamakou, E., Rammou, D., Soulti, K., Piperidou, C., Pavlidis, Nicholas
Publikováno v:
Cancer chemotherapy and pharmacology
Purpose: To investigate the pharmacokinetics of polyethylene glycol-coated liposomal doxorubicin (PLD, Caelyx) when given as a single agent and in combination with the taxanes paclitaxel or docetaxel in humans. Methods: The plasma kinetics of PLD wer
Autor:
Pentheroudakis, George, Pappas, P., Golfinopoulos, Vassilis, Fountzilas, George, Nikolaidou, M., Boumba, V. A., Vougiouklakis, T., Nikiforidis, L., Tzamakou, E., Siarabi, O., Marselos, M., Pavlidis, Nicholas
Publikováno v:
Cancer chemotherapy and pharmacology
Background: Although protracted intravenous 5-fluorouracil is superior to bolus regimens in terms of tumour exposure to the drug during DNA synthesis as well as activity and safety, the oral fluoropyrimidine capecitabine is administered intermittentl
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Briasoulis, E., Tolis, C., Pappas, P., Marselos, M., Nicolaides, C., Nikiforidis, L., Nikolaidou, M., Siarabi, O., Tzamakou, E., Pavlidis, N.
Ejc Supplements
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_____10561::2d5aaad51305b9ad8b9664acd69f3a59
http://olympias.lib.uoi.gr/jspui/handle/123456789/20051
http://olympias.lib.uoi.gr/jspui/handle/123456789/20051
Autor:
Briassoulis, E. Ch, Pentheroudakis, George, Karavasilis, V., Tzamakou, E., Rammou, D., Pavlidis, Nicholas
Publikováno v:
Annals of Oncology
Background: We aimed to define the maximum tolerated dose (MTD) and characterize the toxicity of the combination of pegylated liposomal doxorubicin (PLD; Caelyx™) and weekly paclitaxel (wPTX), and to investigate pharmacokinetics of PLD in this comb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c404139242d04d0d60ef76f0b2abeb2
https://gnosis.library.ucy.ac.cy/handle/7/41419
https://gnosis.library.ucy.ac.cy/handle/7/41419